The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling

Journal of Mathematical Biology

Volumn 48, Issue 4, 2004, Pages 375-422

  Gaffney, E A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Adjuvant chemotherapy modelling; Age structured model; Cell cycle synchronisation

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ALGORITHM; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; CELL DIVISION; DRUG ADMINISTRATION; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; METHODOLOGY; MUTATION; NEOPLASM; PATHOLOGY; PHYSIOLOGY; THEORETICAL MODEL; TIME;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL DIVISION; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, THEORETICAL; MUTATION; NEOPLASMS; S PHASE; TIME FACTORS;

EID: 16344373589     PISSN: 03036812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00285-003-0246-2     Document Type: Article

References (67)

1. Midgley, R., Kerr, D.J.: Seminar in colorectal cancer. Lancet 353, 391-399 (1999)
2. Midgley, R.S., Kerr, D.J.: Adjuvant treatment of colorectal cancer. Cancer Treat. Rev. 23, 135-152 (1997)
3. Midgley, R., Kerr, D.J.: Systemic adjuvant chemotherapy. Management of colorectal cancer, Bleiberg et al., (eds), 1998, p. 126
4. Van Cutsem, E., Dicato, M., Wils, J., Cunningham, D., Diaz-Rubio, E., Glimelius, B., Haller, D., Johnston, P., Kerr, D.J. et al.: Adjuvant treatment of colorectal cancer current expert opinion derived from the third international conference: Perspectives in colorectal cancer, Dublin, 2001. Eur. J. Cancer 38, 1429-1436 (2002)
5. Midgley, R., Kerr, D.J.: ABC of colorectal cancer: Adjuvant chemotherapy. BMJ 321, 1208-1211 (2000)
6. Nicum, S., Midgley, R., Kerr, D.J.: Chemotherapy for colorectal cancer. J. Royal Soc. Med. 93, 416-419 (2000)
7. Tebbutt, N.C., Cattell, E., Midgley, R., Cunningham, D., Kerr, D.: Systemic treatment of colorectal cancer. Eur. J. Cancer 38, 1000-1015 (2002)
8. Midgley, R.S., Kerr, D.J.: Advanced colorectal cancer: Which regimes should we recommend? Preprint, CRC Institute For Cancer Studies, University of Birmingham, U.K.
9. Simpson-Herren, L., Sanford, A.H., Holmquist, J.B.: Effects of surgery on the cell kinetics of residual tumour. Cancer Treat. Rep. 60, 1749-1760 (1976)
10. Gunduz, M., Fisher, B., Saffer, E.A.: Effects of surgical removal on the cell kinetics of residual tumour. Cancer Res. 39, 3861-3865 (1979)
11. Tong, D., Poot, M., Hu, D., Oda, D.: 5-Fluorouracil-induced apoptosis in cultured oral cancer cells. Oral Oncology 36, 236-241 (2000)
12. The Pharmacological Basis of Cancer Chemotherapy. Brockmann, Williams and Wilkins Publishers, Baltimore, 1976, pp. 692-710
13. Chiorino, G., Metz, J.A.J., Tomasoni, D., Ubezio, P.: Desynchronisation rate in cell populations: Mathematical modelling and experimental data. J. Theor. Bio. 208, 185-199 (2001)
14. Bertuzzi, A., Faretta, M., Gandolfi, A., Sinisgalli, C., Starace, G., Valoti, G., Ubezio, P.: Kinetic heterogeneity of an experimental tumour revealed by BrdUrd incorporation and mathematical modelling. Bulletin of Math. Bio. 64, 355-384 (2002)
15. Goldie, J.H., Coldman, A.J., Gudaskas, G.A.: Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treatment Reports 66, 439-449 (1982)
16. Goldie, J.H., Coldman, A.J.: Quantitative model for multiple levels of drug resistance in clinical tumours. Cancer Treat. Rep. 67, 923-931 (1983)
17. Coldman, A.J., Goldie, J.H.: A model for the resistance of tumour cells to cancer chemotherapeutic agents. Math. Biosci. 65, 291-307 (1983)
18. Goldie, J.H., Coldman, A.J.: Application of theoretical models to chemotherapy protocol design. Cancer Treat. Rep. 70, 127-131 (1986)
19. Coldman, A.J., Goldie, J.H.: Drug Resistance in Cancer: Mechanisms and Models. CUP, 1998
20. Day. R.S.: Treatment sequencing, asymmetry and uncertainty: protocol strategies for combination chemotherapy. Cancer Res. 46, 3876-885 (1986)
21. Norton, L., Simon, R.: The Norton-Simon hypothesis revisited. Cancer Treat. Rep. 70, 163-169 (1986)
22. Hudis, C.A., Norton, L.: Adjuvant drug treatment for resectable breast cancer. The Oncologist 2, 351-358 (1997)
23. Belpomme, D.: Diversity of the resistance mechanisms to anticancer cytotoxic drugs. M S-Medecine Sciences 7, 465-472 (1991)
24. Bruce, W.R., Meaker, B.E., Valeriote, F.A.: Comparison of normal hemapoietic and transplanted lymphoma colony froming cells to chemotherapeutic agents administered in-vivo. J. National Cancer Institute 37, 233-245 (1966)
25. Tsurutani, J., Nitta, T., Hirashima, T., Komiya, T., Uejima, H., Tada, H., Syunichi, N., Tohda, A., Fukuoka, M., Nakagawa, K.: Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. Lung Cancer 35, 299-304 (2002)
26. Harnevo, L.H., Agur, Z.: Drug resistance as a dynamic process in a model for multi-step gene amplification under various levels of selection stringency. Cancer Chemo. Pharmacol. 30, 469-476 (1992)
27. Luria, S.E., Delbruck, M.: Mutations of bacteria from virus senstivity. Genetics 28, 493-511 (1943)
28. Law, L.W.: Origin of leukemic cells to folic acid antagonists. Nature 169, 628-629 (1952)
29. Ojima, I., Ferlini, C.: New insights into drug resistance in cancer. Chemistry & Biology 10, 583-589 (2003)
30. The Holland-Frei Cancer Medicine, Edition 5, American Cancer Society, BC Decker Inc, 2000. Chap. 38
31. The Holland-Frei Cancer Medicine. Edition 5, American Cancer Society, BC Decker Inc, 2000. Chap. 40
32. Rew, D.A., Wilson, G.D.: Cell production rates in human tissues and tumours and their significance. Part II: clinical data. Eur. J. Surgical Oncology 26, 405-417 (2000)
33. Kemeny, N., Huang, Y., Cohen, A.M., Shi, W., Conti, J.A. et al.: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases. New England J. Med. 341, 2039-2048 (1999)
34. Kemeny, N., Fata, F.: Hepatic arterial chemotherapy. The Lancet Oncology 2, 418-428 (2001)
35. Kemeny, N.: Regional chemotherapy of colorectal cancer. Eur. J. Cancer 31A, 1271-1276 (1995)
36. Wheldon, T.E.: Mathematical Models in Cancer Research. Adam Hilger Publishers, Bristol, 1988
37. Gardner, S.N.: Modelling multi-drug chemotherapy: tailoring treatment to individuals. J. Theor. Biol. 214, 181-207 (2002)
38. Birkhead, B.G., Rakin, E.M., Gallivan, S., Dones, L., Rubens, R.D.: A mathematical model of the development of drug resistance to cancer chemotherapy. Eur. J. Cancer Clin. Oncol. 23, 1421-1427 (1987)
39. Panetta, J.C., Adam, J.: A mathematical model of cycle-specific chemotherapy. Mathl. Comput. Modelling 22, 67-82 (1995)
40. Thomas, D.M., Zalcberg, J.R.: 5-Fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clinical and Experimental Pharmacology and Physiology 25, 887-895 (1998)
41. Murray, J.M.: The optimal scheduling of two drugs with simple resistance for a problem in cancer chemotherapy. IMA J. Math. Appl. Med. Bio. 14, 283-303 (1997)
42. Coldman, A.J., Murray, J.M.: Optimal control for a stochastic model of cancer chemotherapy. Math. Biosci. 168, 187-200 (2000)
43. Goldbeter, A., Claude, D.: Time-patterned drug administration: Insights from a modelling approach. Int. Chronobiology 19, 157-175 (2002)
44. Dibrov, B.F.: Resonance effect in self renewing tissues. J. Theor. Bio. 192, 15-33 (1998)
45. Dibrov, B.F., Zhabotinsky, A.M., Yu, A., Neyfakh, M., Orlova, P., Churikova, L.I.: Mathematical model of cancer chemotherapy. Periodic schedules of phase-specific cytotoxic-agent administration increasing the selectivity of therapy. Math. Biosci. 73, 1-31 (1985)
46. Webb, G.: Resonance phenomena in cell population chemotherapy models. Rocky Mountain J. Math. 20, 1195-1216 (1990)
47. Halloran, M.E.: Persistence, drugs and rock-n-roll. Trends in Ecology & Evolution 7, 212-214 (1992)
48. Agur, Z., Arnon, R., Schechter, B.: Reduction of cytotoxicity to normal tissues by new regimens of phase-specific drugs. Math. Biosci. 92, 1-15 (1988)
49. Webb, G.: A nonlinear cell population model of periodic chemotherapy treatment. Recent Trends in Ordinary Differential Equations, Series in Applicable Analysis, World Scientific Publishing Company, 1992, pp. 569-583
50. Webb, G.: A cell population model of periodic chemotherapy treatment. Biomedical Modeling and Simulation, Elsevier Science Publishers, 1992, pp. 83-92
51. Cojocaru, L., Agur, Z.: Theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. Math. Bio. 109, 85-97 (1992)
52. n series for predicting optimal chemotherapy treatment. Random and Computational Dynamics 2, 279-286 (1994)
53. Webb, G., Johnson, M.: Resonances in age structured cell population models of periodic chemotherapy. Int. J. Appl. Sci. Comput. 3, 57-67 (1996)
54. Shochat, E., Hart, D., Agur, Z.: Using computer simulations for evaluating the efficacy of breast cancer chemotherapy protocols. J. Math. Models and Methods in Appl. Sci. 9, 599-615 (1999)
55. Agur, Z., Arnon, R., Sandak, B., Schechter, B.: Zidovudine toxicity to murine bone marrow may be affected by the exact frequency of drug administration. Experimental Hematology 19, 364-368 (1991)
56. Agur, Z., Arnon, R., Schechter, B.: Effect of the dosing interval on survival and myelotoxicity in mice treated by cytosine arabinoside. Eur. J. Cancer 28A, 1085-1090 (1992)
57. Ubezio, P., Tagliabue, G., Schechter, B., Agur, Z.: Increasing 1-D-Arabinofuranosylcytosine ecacy by scheduled dosing intervals based on direct measurement of bone marrow cell kinetics. Cancer Res. 54, 6446-6451 (1994)
58. Agur, Z.: Resonance and anti-resonance in the design of chemotherapeutic protocols. J. Theor. Med. 1, 237-245 (1998)
59. Anderson, L.K., Mackey, M.C.: Resonance in periodic chemotherapy: a case study of acute myelogenous leukaemia. J. Theor. Bio. 209, 113-130 (2001)
60. Swan, G.W.: Role of optimal control theory in cancer chemotherapy. Math. Biosci. 101, 237-284 (1990)
61. Panetta, J.C., Chaplain, M.A.J., Cameron, D.: Modelling the effects of paclitaxel and cisplatin on breast and ovarian cancer. J. Theor. Med. 3, 11-23 (2000)
62. Dyson, J., Villella-Bressan, R., Webb, G.F.: Asynchronous exponential growth in an age structured population of proliferating and quiescent cells. Math. Biosci. 177-178, 73-78 (2002)
63. Wolfe, S.L.: Introduction to Cell and Molecular Biology. Wadsworth, 1995
64. Teukolsky, S.A. et al.: Numerical Recipes in Fortran. 2nd ed, Ch. 19, W.H. Press, CUP, 1992
65. Bender, C.M., Orszag, S.A.: Advanced Mathematical Methods for Scientists and Engineers. Asymptotic Methods and Perturbation Theory. Springer, 1999
66. Franks, L.M., Teich, N.M., eds.: Introduction to The Cellular and Molecular Biology of Cancer. Third Edition. Oxford University Press, 1998
67. US National Library of Medicine - Medical Subject Headings, National Institute of Health. http://www.nlm.nih.gov/cgi/mesh/2K/MB_cgi?term=Floxuridine